

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Heather Spencer Feigelson, PhD, MPH		POSITION TITLE Investigator	
eRA COMMONS USER NAME (credential, e.g., agency login)			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Colorado State University, Fort Collins, CO	BS	1986	Environmental Health
San Diego State University, San Diego, CA	MPH	1991	Epidemiology
University of California, Los Angeles, CA	PhD	1995	Epidemiology

A. Positions and Honors.

Professional Experience

- 1996-1998 Postdoctoral Fellow, Department of Preventive Medicine, University of Southern California, Los Angeles, CA
- 1998-1999 Assistant Professor, Department of Preventive Medicine, University of Southern California, Los Angeles, CA
- 1999- Adjunct Asst Professor, Department of Preventive Medicine, University of Southern California, Los Angeles, CA
- 1999-2006 Senior Epidemiologist, Epidemiology and Surveillance Research, American Cancer Society, National Home Office, Atlanta, GA
- 2003- Adjunct Associate Professor, Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA
- 2006-2008 Strategic Director, Epidemiology and Surveillance Research, Genetic Epidemiology, American Cancer Society, National Home Office, Atlanta, GA
- 2008- Investigator, Institute for Health Research, Kaiser Permanente, Denver, CO

Editorial Boards and Memberships and Other Professional Activities

Breast Cancer Research Journal

Member, American Association for Cancer Research

Member, American Society for Human Genetics

Member, American Society of Preventive Oncology

Member, Molecular Epidemiology Working Group of the America Association of Cancer Research

Reviewer, CDMRP Breast Cancer Research Program, 2001

Reviewer, CDMRP Prostate Cancer Research Program, 2001

Reviewer, Canadian Breast Cancer Research Program, 2001-2002

Member, AACR 2003 Program Committee, Genetic of Risk and Outcome Section of the Epidemiology and Biostatistics Subcommittee, 2003

Concept Reviewer for NHLBI Women’s Health Initiative Follow-up Study, 2003

Member, AACR 2005 Program Committee, Genetic of Risk and Outcome Section of the Epidemiology and Biostatistics Subcommittee, 2004

Site Visit Peer Reviewer, NCI Division of Cancer Epidemiology and Genetics, Hormonal and Reproductive Epidemiology Branch, September 2006

Panel Member, Health Disparities in Estrogen Receptor Negative Breast Cancer Think Tank, National Cancer Institute, 2007

Grant Review for Breast Cancer Campaign (UK), 2007

Reviewer for Administrative Supplements for Replication and Fine-Mapping Research for The Genes, Environment and Health Initiative (GEI), 2008

Honors

Outstanding Student Award in Environmental Health, 1986

Outstanding Student Award in Epidemiology and Biostatistics, 1991

Graduate School of Public Health Outstanding Student Award, 1991
Cancer Education and Control Fellowship, 1992-1995
American Society for Preventive Oncology New Investigators Workshop, 1994
Society for Epidemiology Research Student Workshop, 1994

B. Peer-Reviewed Publications.

1. Criqui MH, Langer RD, Fronek A, **Feigelson HS**, Klauber MR, McCann TJ, Browner D. Peripheral arterial disease and subsequent all-cause, cardiovascular and coronary heart disease mortality: a 10-year prospective study. N Engl J Med 1992; 326:381-386.
2. **Feigelson HS**, Criqui MH, Fronek A, Langer RD, Molgaard CA. Screening for peripheral arterial disease: The sensitivity, specificity, and predictive value of noninvasive tests. Am J Epidemiol 1994; 140:526-34.
3. Fronek A, Criqui MH, **Feigelson HS**. A simple screening method for peripheral occlusive disease (letter). J Vasc Surg 1995; 22:122.
4. Langer RD, Criqui MH, **Feigelson HS**, McCann TJ, Hamburger RN. IgE predicts future non-fatal myocardial infarction in men. J Clin Epidemiol 1996; 49:203-209.
5. Feigelson BJ, Acosta JA, **Feigelson HS**, et al. T1 breast carcinoma in women 70 years of age and older may not require axillary lymph node dissection. Am J Surgery 1996; 172:487-490.
6. **Feigelson HS**, Henderson BE. Estrogens and Breast Cancer. Carcinogenesis 1996; 17:2279.
7. **Feigelson HS**, Ross RK, Yu MC, Coetzee GA, Reichardt JKV, Henderson BE. Genetic susceptibility to cancer from exogenous and endogenous exposures. J Cell Biochem 1996; 25S:15-22.
8. Crocitto LE, **Feigelson HS**, Yu MC, Kolonel LC, Henderson BE, Coetzee GA. A polymorphism in intron 6 of the CYP17 gene. Clinical Genetics 1997; 52:68-69.
9. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Research 1997; 57:1063-1065.
10. **Feigelson HS**, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE. CYP17 polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Research 1998; 58:585-587.
11. Ross RK, Pike MC, Coetzee GA, Reichardt JKV, Yu MC, **Feigelson HS**, Stanczyk FZ, Kolonel LN, Henderson BE. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Research 1998; 58:4497-4504.
12. **Feigelson HS**, McKean-Cowdin R, Pike MC, Coetzee GA, Kolonel LN, Nomura AMY, LeMarchand L, Henderson BE. CYP17 polymorphism predicts use of hormone replacement therapy. Cancer Research 1999; 59:3908-3910.
13. **Feigelson HS**, Henderson BE. Future possibilities in the prevention of breast cancer: role of genetic variation in breast cancer prevention. Breast Cancer Res 2000;2:277-282.
14. **Feigelson HS**, Rodriguez C, Robertson AS, Jacobs EJ, Calle EE, Reid YA, Thun MJ. Determinants of DNA yield and quality from buccal cell samples collected with mouthwash. Cancer Epidemiol Biomark Prev 2001; 10:1005-1008.
15. **Feigelson HS**, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE. Building a multi-genic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Research 2001; 61:785-789.
16. McKean-Cowdin R, **Feigelson HS**, Pike MC, Coetzee GA, Kolonel LN, Henderson BE. Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. Cancer Research 2001; 61:848-849.
17. **Feigelson HS**, Calle EE, Robertson AS, Wingo PA, Thun MJ. Alcohol consumption increases the risk of fatal breast cancer. Cancer Causes and Control 2001; 12:875-880.
18. Rodriguez C, Jacobs EJ, Patel A, Calle EE, **Feigelson HS**, Fakhrabadi-Shokoohi D, Thun MJ. Jewish ethnicity and prostate cancer mortality in two large U.S. cohorts. Cancer Causes Control 2002;13:271-277.
19. **Feigelson HS**, McKean-Cowdin R, Henderson BE. Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis (Letter). Mutagenesis 2002;17:445-446.
20. **Feigelson HS**, Jonas C, Robertson A, McCullough M, Calle EE, Thun MJ. Alcohol, folate, methionine and risk of incident breast cancer in the American Cancer Society CPS-II Nutrition Cohort. Cancer Epidemiol Biomark Prev 2003;12:161-164.

21. **Feigelson HS**, Rodriguez C, Jacobs EJ, Diver WR, Thun MJ, Calle EE. No association between the progesterone receptor gene +331G/A polymorphism and breast cancer. Cancer Epidemiol Biomark Prev, 2004, 13:1084-1085.
22. **Feigelson HS**, Jonas CR, Teras LR, Calle EE, Thun MJ. Weight gain, body mass index, hormone replacement therapy and postmenopausal breast cancer in a large prospective cohort. Cancer Epidemiol Biomark Prev, 2004, 13:220-224.
23. Jacobs EJ, Thun MJ, Connell CJ, Rodriguez C, Henley SJ, **Feigelson HS**, Patel AV, Flanders WD, Calle EE. Aspirin and other non-steroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomark Prev, 2005, 14:261-264.
24. McKean-Cowdin R, **Feigelson HS**, Xia LY, Pearce CL, Thomas DC, Stram DO, Henderson BE. BRCA1 variants in a family study of African-American and Latina women. Human Genetics, 2005;116:497-506.
25. McCullough ML, Rodriguez C, Diver WR, **Feigelson HS**, Stevens V, Thun MJ, Calle EE. Dairy, calcium and vitamin D intake and postmenopausal breast cancer risk in the CPS II Nutrition Cohort. Cancer Epidemiol Biomark Prev 2005;14(12):1-7.
26. Hunter DJ, Riboli E, Haiman CA, et al. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer, 2005, 5:977-985.
27. Patel AV, Calle EE, Pavluck AL, **Feigelson HS**, Thun MJ, Rodriguez C. A prospective study of XRCC1 polymorphisms and breast cancer risk. Breast Cancer Research, 2005, 7:R1168-73. <http://breast-cancer-research.com/content/7/6/R1168>.
28. McCullough ML, **Feigelson HS**, Diver WR, Patel AV, Thun MJ, Calle EE. Risk factors for fatal breast cancer in African American and white women in a large U.S. prospective cohort. Am J Epid, 2005, 162:734-42. Epub 2005 Aug 24.
29. Small CM, Marcus M, Sherman SL, Sullivan AK, Manatunga A, **Feigelson HS**. CYP17 genotype predicts serum hormone levels among premenopausal women. Human Reproduction, 2005, 8:2162-7. Epub 2005 May 5.
30. **Feigelson HS**, Pearce CL, Diver RW, McKean-Cowdin R. CYP17 as a candidate gene for hormone-related cancers among women: a review of the evidence, Int J Cancer Prev, 2005; 2:25-35.
31. **Feigelson HS**, Cox DG, Cann HM, et al. Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. Cancer Res 2006;66(4):2468-75.
32. Small CM, Manatunga A, Klein M, **Feigelson HS**, Dominguez CE, McChesney R, Marcus M. Menstrual cycle characteristics: Associations with fertility and spontaneous abortion. Epidemiology 2006;17:52-60.
33. **Feigelson HS**, Cox DG, Cann HM, Washolder S, et al. Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. Cancer Res 2006;66(4):2468-75.
34. Jacobs EJ, **Feigelson HS**, Bain EB, Brady KA, Rodriguez C, Stevens VL, Patel AV, Thun MJ, Calle EE. Polymorphisms in the vascular endothelial growth factor gene and breast cancer incidence in the Cancer Prevention Study II Cohort. Breast Cancer Res 2006;8:R22.
35. **Feigelson HS**, Patel AV, Diver WR, Stevens VL, Thun MJ, Calle EE. Transforming growth factor B receptor type I (TGFBR1) and transforming growth factor B1 (TGFB1) polymorphisms are not associated with postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev Cancer Epid, Biomark Prev, 2006;15:1236 -7.
36. **Feigelson HS**, Patel AV, Teras LR, Gansler T, Thun MJ, Calle EE. Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women. Cancer, 2006;107:12 -21.
37. Cox DG, Blanche H, Pearce CL, et al. A comprehensive analysis of the AR gene and risk of breast cancer: results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Breast Cancer Research 2006, 8:R54.
38. McCullough ML, Stevens VL, Diver WR, et al. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Research 2007, 9:R9 doi:10.1186/bcr1642.I
39. Haiman CA, Dossus L, Setiawan VW, et al. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women: results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Research 2007; 67:1893-7.

40. Schumacher FR, **Feigelson HS**, Hunter DJ, et al. A common 8q24 variant in breast and prostate cancer from a large nested case-control study. Cancer Research 2007; 67:2951-6.
41. **Feigelson HS**, Rodriguez C, Welch R, et al. Successful genome-wide scan in paired blood and buccal samples. Cancer Epid Biomark Prev 2007; 16:1140-7.
42. Stevens VL, McCullough M, Pavluck A, et al. Association of polymorphisms in one-carbon metabolism genes and post menopausal breast cancer incidence. Cancer Epidemiol Biomarkers Prev 2007; 16:1140-7.
43. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007; May 27 (Epub).
44. Chen Chen YC, Kraft P, Bretsky P, et al. Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev 2007;16:1973-81.
45. Stevens VL, Patel A, **Feigelson HS**, et al. Cryopreservation of Whole Blood Samples Collected in the Field for a Large Epidemiologic Study. Cancer Epidemiol Biomarkers Prev 2007; 16:2160-3.
46. Setiawan VW, Schumacher FR, Haiman CA, et al. CYP17 genetic variation and risk of breast and prostate cancer. Cancer Epidemiol Biomarkers Prev, 2007;16: 2237-46.
47. Cox DG, Bretsky P, Kraft P, et al. Haplotypes of the estrogen receptor beta (ESR2) gene and breast cancer risk. Int J Cancer. 2008;122(2):387-92.
48. McCullough ML, Patel AV, Patel R, et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev, 2008;17: 73-79.
49. Thomas G, Jacobs KB, Yeager M, et al. Multiple novel loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008 Mar;40(3):310-5. Epub 2008 Feb 10.
50. Ahn J, Berndt SI, Wacholder S, et al. Variation in KLK genes, prostate specific antigen, and risk of prostate cancer. Nature Genetics 2008 Sep;40(9):1032-4.
51. Rodriguez C, **Feigelson HS**, Deka A, Patel AV, Jacobs EJ, Thun MJ, Calle EE. Post-menopausal Hormone Therapy and Lung Cancer Risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev, in press.
52. Patel AV, **Feigelson HS**, Talbot JT, McCullough ML, Rodriguez C, Patel RC, Thun MJ, Calle EE. The role of body weight in the relationship between physical activity and endometrial cancer: results from a large cohort of US women. Int J Cancer, in press.